Given that the reduction of CAV1 was not significantly correlated with postsurgical recurrence of patients with stage I lung adenocarcinoma, CAV1 is unsuitable as a coordinated molecule to improve the predictive power of EFHD2. The gene discussed is CAV1; the disease is lung adenocarcinoma.